Clinical Trial Update: Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pegylated interferon alfa + ribavirin + daclatasvir in treatment-naïve hepatitis C patients (genotypes 1 and 4) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• Peginterferon alfa (pegylated interferon alpha)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 3 | Status: WITHDRAWN